Membrane-bound IL-7 Engineered TIL therapy for advanced ovarian cancer
crossref(2024)
摘要
Abstract Ovarian cancer lacks effective therapy. Here, we reported three metastatic ovarian cancer patients administrated with a noval TIL therapy, which was designed glycosylphosphatidylinositol-anchored membrane-bound interleukin-7 (mbIL-7-GPI) to engineer TILs (mbIL-7-TIL) through piggyBac transposon system. In three advanced ovarian cancer patients, infusion of mbIL-7-TILs showed endurable toxicity and prolonged clinical response. After infusion, peripheral mbIL-7-TILs peaked around 5-7 days and then sharply decreased. We found that several clones of engineered T cell and subsequent clones of original T cells underwent significant proliferation in patient 1. Seven months post infusion, mbIL-7-TILs could be detected in tumor liquefactive necrosis of patient 2. These findings indicated that mbIL-7-TILs could efficiently home to tumor lesions and sustainably enhance antitumor immunity in situ, suggesting potent therapeutics to treat advanced OC.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要